Numakawa T, Kajihara R
Molecules. 2025; 30(4).
PMID: 40005159
PMC: 11857940.
DOI: 10.3390/molecules30040848.
Nanda S, Yi D
Micromachines (Basel). 2024; 15(11).
PMID: 39597194
PMC: 11596582.
DOI: 10.3390/mi15111382.
Chongtham A, Agrawal N
Dose Response. 2024; 22(4):15593258241291652.
PMID: 39410958
PMC: 11475233.
DOI: 10.1177/15593258241291652.
Wu Y, Ma B, Liu C, Li D, Sui G
Int J Mol Sci. 2024; 25(18).
PMID: 39337671
PMC: 11432175.
DOI: 10.3390/ijms251810187.
Kim L, Kundu B, Moretti P, Lozano A, Rahimpour S
Neurotherapeutics. 2024; 21(6):e00452.
PMID: 39304438
PMC: 11585891.
DOI: 10.1016/j.neurot.2024.e00452.
Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first-in-human study.
Gao L, Bhattacharyya A, Beers B, Kaushik D, Bredlau A, Kristensen A
Br J Clin Pharmacol. 2024; 90(12):3242-3251.
PMID: 39155237
PMC: 11602954.
DOI: 10.1111/bcp.16202.
Mutant Huntingtin Drives Development of an Advantageous Brain Early in Life: Evidence in Support of Antagonistic Pleiotropy.
Neema M, Schultz J, Langbehn D, Conrad A, Epping E, Magnotta V
Ann Neurol. 2024; 96(5):1006-1019.
PMID: 39115048
PMC: 11496017.
DOI: 10.1002/ana.27046.
Exploring the therapeutic potential: Apelin-13's neuroprotective effects foster sustained functional motor recovery in a rat model of Huntington's disease.
Torkamani-Dordshaikh S, Darabi S, Norouzian M, Bahar R, Beirami A, Moghaddam M
Anat Cell Biol. 2024; 57(3):419-430.
PMID: 39079710
PMC: 11424562.
DOI: 10.5115/acb.23.284.
Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant .
Iwamoto N, Liu Y, Frank-Kamenetsky M, Maguire A, Tseng W, Taborn K
Mol Ther Nucleic Acids. 2024; 35(3):102246.
PMID: 39027419
PMC: 11255113.
DOI: 10.1016/j.omtn.2024.102246.
Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease.
Shafie A, Ashour A, Anwar S, Anjum F, Hassan M
Arch Pharm Res. 2024; 47(6):571-595.
PMID: 38764004
DOI: 10.1007/s12272-024-01499-w.
Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders.
Lui A, Do T, Alzayat O, Yu N, Phyu S, Santuya H
Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675388
PMC: 11054060.
DOI: 10.3390/ph17040426.
Mutant huntingtin protein induces MLH1 degradation, DNA hyperexcision, and cGAS-STING-dependent apoptosis.
Sun X, Liu L, Wu C, Li X, Guo J, Zhang J
Proc Natl Acad Sci U S A. 2024; 121(13):e2313652121.
PMID: 38498709
PMC: 10990133.
DOI: 10.1073/pnas.2313652121.
Lowering mutant huntingtin by small molecules relieves Huntington's disease symptoms and progression.
Bahat A, Itzhaki E, Weiss B, Tolmasov M, Tsoory M, Kuperman Y
EMBO Mol Med. 2024; 16(3):523-546.
PMID: 38374466
PMC: 10940305.
DOI: 10.1038/s44321-023-00020-y.
Rapid and high-purity differentiation of human medium spiny neurons reveals LMNB1 hypofunction and subtype necessity in modeling Huntington's disease.
Wu J, Ren J, Cui H, Xie Y, Tang Y
Inflamm Regen. 2024; 44(1):7.
PMID: 38360694
PMC: 10870681.
DOI: 10.1186/s41232-024-00320-x.
Rodent Models of Huntington's Disease: An Overview.
Nittari G, Roy P, Martinelli I, Bellitto V, Tomassoni D, Traini E
Biomedicines. 2023; 11(12).
PMID: 38137552
PMC: 10741199.
DOI: 10.3390/biomedicines11123331.
Charge within Nt17 peptides modulates huntingtin aggregation and initial lipid binding events.
Stonebraker A, Hankin R, Kapp K, Li P, Valentine S, Legleiter J
Biophys Chem. 2023; 303:107123.
PMID: 37852163
PMC: 10843285.
DOI: 10.1016/j.bpc.2023.107123.
In planta expression of human polyQ-expanded huntingtin fragment reveals mechanisms to prevent disease-related protein aggregation.
Llamas E, Koyuncu S, Lee H, Wehrmann M, Gutierrez-Garcia R, Dunken N
Nat Aging. 2023; 3(11):1345-1357.
PMID: 37783816
PMC: 10645592.
DOI: 10.1038/s43587-023-00502-1.
The Huntington's Disease Gene in an Italian Cohort of Patients with Bipolar Disorder.
Ferrari C, Capacci E, Bagnoli S, Ingannato A, Sorbi S, Nacmias B
Genes (Basel). 2023; 14(9).
PMID: 37761821
PMC: 10531383.
DOI: 10.3390/genes14091681.
BDNF and Cerebellar Ataxia.
Lalonde R, Hernandez M, Strazielle C
Curr Drug Res Rev. 2023; 16(3):300-307.
PMID: 37609676
DOI: 10.2174/2589977515666230811093021.
Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration.
Estevez-Fraga C, Altmann A, Parker C, Scahill R, Costa B, Chen Z
Brain. 2023; 146(11):4532-4546.
PMID: 37587097
PMC: 10629790.
DOI: 10.1093/brain/awad275.